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Middle ear cholesteatoma is destructive to auditory ossicles and temporal bone, and treatment usually
requires surgical removal of all epithelial content. Epidermal growth factor (EGF) can stimulate the growth
and differentiation of a variety of mammalian cells, including epithelial cells. Our study used the avidin-
biotin complex technique to evaluate the expression of EGF in 40 cases of middle ear cholesteatoma (active
cholesteatoma, 31 cases; inactive cholesteatoma, 9 cases) and 34 normal postauricular skin samples. In
middle ear cholesteatoma, EGF was expressed in squamous epithelium in 21 cases (53%), fibroblasts in
two cases (5%), and cholesteatoma endothelium in two cases (5%). In normal postauricular skin, EGF was
expressed in squamous epithelium in 14 samples (41%), fibroblasts in one sample (3%), and endothelium
in none. No statistical difference in EGF expression was found between cholesteatoma and normal
postauricular skin samples. These results show that the distribution of EGF in middle ear cholesteatoma
is not deranged and that the progression of cholesteatoma might be induced by the release of factors from
the cholesteatoma matrix via autocrine stimulation, or by inflammatory cells of the subepithelial tissue
through paracrine stimulation, or in both of these ways.
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Cholesteatoma is a destructive lesion of the middle ear or
mastoid process that produces complications through
erosion of the temporal bone with involvement of the
contained neural and vascular structures and adjacent
central nervous system structures. Histologically, chole-
steatoma is composed of an accumulation of desquamated
keratin arising from the squamous epithelium [1]. Recent
research has attributed an important role in keratinocyte
proliferation to numerous growth factors and cytokines,
and one of these is epidermal growth factor (EGF) [2]. EGF,
a single-chain polypeptide consisting of 53 amino acids, can
stimulate the growth and differentiation of a variety of
mammalian cells, including epithelial cells. The level of
EGF (in mammalian cells, including epithelial cells) is related
to the state of differentiation and the ability of keratinocytes
to differentiate [3]. Its expression in keratinocytes, which
depends on the state of differentiation, may be considered
a marker indicating the state of proliferation and terminal
differentiation [4]. Using immunohistochemistry, we
attempted to elucidate the site and degree of EGF localization
in different types of cells involved in middle ear chole-
steatoma. Immunohistochemical staining indicates the sites
where EGF may be synthesized. We aimed to identify the
expression of EGF in examined cells and the role EGF plays
in the growth of cholesteatoma.
MATERIALS AND METHODS
Cholesteatoma specimens were obtained from 40 patients
(mean age, 38 years; range, 19–67 years) who underwent
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middle ear surgery at the Department of Otorhinolaryn-
gology, Kaohsiung Medical University Hospital, in 2000 to
2002. Specimens from 31 patients with a thicker matrix
(accumulation of keratin debris due to active proliferation
and differentiation of keratinocytes) were labeled active
cholesteatoma. Specimens from the remaining nine cases
with less debris and granulation tissue or thin matrix were
labeled inactive cholesteatoma.
For the control, normal postauricular skin specimens
were obtained from the 40 patients as they underwent
middle ear surgery. If any inflammation or cholesteatoma
cells were suspected to be present, the specimens were
excluded; 34 patients were finally included (mean age,
43 years; range, 19–51 years).
Immunohistochemical staining
Immediately after surgery, specimens were fixed in 10%
buffered formalin solution overnight, dehydrated,
embedded in paraffin, and sliced into 4 +m sections. After
deparaffinization and washing, endogenous peroxidase
was inhibited using a methanolic solution of 0.3% hydrogen
peroxide and then blocked with 10% normal horse serum
and 1% bovine serum albumin for 30 minutes. After a brief
rinse, sections were incubated with the EGF receptor (EGF-
R) monoclonal antibody (1:20; BioGenex Laboratories Inc,
San Ramon, CA, USA) at room temperature for 120 minutes.
They were then washed in phosphate-buffered saline,
incubated for 30 minutes with biotinylated anti-mouse
immunoglobulin G (IgG), and treated with avidin-biotin
complex for 30 minutes; 3-3’-diaminobenzidine was then
applied as a chromogen. Sections were visualized after
counterstaining with Mayer’s hematoxylin. EGF labeling
was considered positive if one EGF-positive cell was present.
Omission of the primary antibody was used as a negative
control and EGF expression in breast cancer samples was
used as a positive control (brownish color and gloss strength)
[5]. Differences between the distribution patterns in the
squamous epithelium, fibroblasts, and endothelial cells in
the two groups (cholesteatoma and normal postauricular
skin) were tested using the Chi-squared test.
RESULTS
Middle ear cholesteatoma
EGF expression in the cytoplasm of cholesteatoma epithe-
lium (Figure 1) was the same as that in breast cancer (Figure
2). In the 31 cases of active cholesteatoma, EGF staining
was strongly positive or positive in 17 cases (55%) in the
squamous epithelium, in two cases (6%) in fibroblasts, and
in two cases (6%) in the endothelium (Table 1). Four of the
nine cases (44%) of inactive cholesteatoma had strongly
positive or positive EGF staining in the squamous epithelium
(Table 1). Active cholesteatoma showed more EGF immuno-
reactivity than inactive cholesteatoma. EGF immuno-
reactivity was greatest in the squamous epithelium and
decreased in the fibroblasts and endothelium.
Postauricular skin
In the 34 normal postauricular skin samples, EGF staining
was positive in 14 cases (41%) in the squamous epithelium,
in one case (3%) in fibroblasts, and in no cases in the
endothelium (Table 2). Cholesteatomas had greater EGF
expression than normal postauricular skin in the squamous
epithelium, but this did not reach statistical significance.
Figure 1. Epidermal growth factor (EGF) staining in cholesteatoma:
squamous epithelium (arrows), endothelium (large arrow), and fibroblasts
(hollow arrow). (Original magnification, = 600.)
Figure 2. Epidermal growth factor (EGF) immunostaining in breast
cancer (arrow). (Original magnification, = 440.)
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DISCUSSION
Middle ear cholesteatoma is a pathologic condition that
develops as a result of the extension or depression of the
flaccida or tensa of the tympanic membrane. Most
cholesteatomas concomitantly have an inflammatory
reaction in keratinocytes. Inflammatory cells may actively
participate in the aberrant functioning of the cholesteatoma
epithelium by releasing various cytokines. These are then
involved in hypervascularization, a migratory and invasive
epithelium, and hyperproliferation [1,6]. The growth of
cholesteatoma seems not to cease and the cholesteatoma
may recur many years postoperatively unless it is completely
eradicated. The clinical characteristics of cholesteatoma
indicate that it may have a hyperproliferative ability and
that progression may be induced by the release of factors
from the cholesteatoma matrix via autocrine stimulation,
by inflammatory cells of the subepithelial connective tissue
via paracrine stimulation, or in both ways [7]. Different
growth factors and cytokines have been identified as being
involved in the pathogenesis of cholesteatoma. EGF,
transforming growth factor _ (TGF-_), and interleukin 1
(IL-1) seem to be responsible for the increased proliferation
rate of keratinocytes [3].
EGF is a single-chain polypeptide made up of 53 amino
acids. It has been structurally well characterized in both
animals and humans. Its numerous biologic effects include
stimulation of extracellular compounds transported to
epithelial cells, activation of glycolysis, initiation of DNA
synthesis, activation of RNA and protein synthesis, and
increased synthesis of extracellular macromolecules. EGF
can induce the proliferation of epithelial and endothelial
cells, fibroblasts and keratinocytes [4,8]. In this study, we
used immunohistochemical staining to identify the
distribution of EGF in several cell types in cholesteatoma
and evaluated the role and mechanism of action of EGF in
cholesteatoma.
More EGF-positive staining was found in the squamous
epithelium in active cholesteatomas than inactive
cholesteatomas, which showed that active cholesteatoma
epithelium proliferated faster than inactive cholesteatoma
epithelium. In postauricular skin, there was more EGF
staining in the squamous epithelium than in other tissues.
The orderly pattern of EGF staining was not deranged in
cholesteatoma epithelium, which was similar to that in
normal postauricular skin. This may reflect the high
proportion of inactive cholesteatomas and apoptosis in our
specimens, which led to no significant difference in EGF
expression in cholesteatoma and normal skin tissue.
Angiogenesis is particularly important in pathologic
processes, including inflammation. Because proliferating
tissues such as middle ear cholesteatoma require an
enhanced blood supply, angiogenesis appears to be a pre-
requisite for the expansion of the cholesteatoma matrix.
Table 1. Epidermal growth factor immunoreactivity in active (n = 31) and inactive (n = 9) cholesteatoma
EGF ++ or + EGF – Total
Active Inactive Active Inactive
Squamous epithelium 17 4* 14 5 40
Fibroblasts 2 0* 29 9 40
Endothelium 2 0* 29 9 40
EGF = epidermal growth factor; ++ = strongly positive; + = positive; – = negative. *Active vs inactive, p > 0.05.
Table 2. Positive epidermal growth factor staining in middle ear cholesteatoma and postauricular skin
Cholesteatoma Postauricular skin
++ or +1 – ++ or +2 –
Squamous epithelium* 21 19 14 20
Fibroblasts* 2 38 1 33
Endothelium* 2 38 0 34
++ = strongly positive; + = positive; – = negative. *1 vs 2, p > 0.05.
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Angiogenesis enables and supports the sustained migration
of keratinocytes into the middle ear cavity [2]. Previously,
TGF-_ and EGF were thought to be potent angiogenic
factors that stimulated endothelial cells. Sudhoff et al
examined angiogenesis in middle ear cholesteatoma and
found overexpression of both EGF and EGF-R, raising the
possibility that EGF stimulates endothelial cells and so
induces angiogenesis [7]. In this study, EGF staining of
endothelium was more common in active than in inactive
cholesteatoma, but there was no significant difference
between inactive cholesteatoma and normal postauricular
skin. Because monocytes, macrophages, and infiltrating
leukocytes are known to produce cytokines such as EGF
and TGF-_, angiogenesis might be induced by inflammatory
cells. These processes may be complicated by many growth
factors and may be closely related to the degree of
inflammation. Our study suggests that EGF is also a product
of endothelial cells and so is a candidate for involvement in
the development of cholesteatoma not only through
paracrine regulation but also via autocrine regulation.
Hildmann and Sudhoff reported that EGF expression is
related to the degree of inflammation within the perimatrix
[9]. There was no significant difference in EGF distribution
between active and inactive cholesteatoma and postauricular
skin in our study. Palacios et al reported that the stimulation
effect of EGF is dose-dependent [10]. At lower concentra-
tions, EGF has a stimulatory effect on mucosal epithelium.
However, at the highest concentration, it appears to inhibit
cellular growth. Increased EGF expression in middle ear
cholesteatoma has been described for epithelial cells [11,
12], and high EGF levels have been demonstrated in chole-
steatoma debris [13]. In the human ear, active cholestea-
tomas have greater immunoreactivity with EGF in their
epidermal layers than inactive cholesteatomas [14]. Bujia et
al found that basal cells of the epidermis and human
cholesteatoma contain high concentrations of EGF and cell
receptors [3]. Fibroblasts of cholesteatoma are more ag-
gressive than fibroblasts of ear canal skin, which seems to
be due to EGF. EGF activates tyrosine protein kinase in the
receptor, which induces mitotic activity. Yetiser et al showed
that higher levels of cytokines in patients with cholesteatoma
confirm that the destructive behavior of cholesteatoma is
likely to be mediated by cytokines and EGF and is the result
of keratinocyte activity [15].
How does the epithelium grow into the middle ear? There
are many theories, including the metaplasia hypothesis, the
retraction theory and direct ingrowth from eardrum per-
foration. The squamous epithelium that migrates into the
middle ear cavity uses granulation tissue and the organized
effusion as a bridge, resulting in migration and cholesteatoma
formation [16]. Besides the proliferation effect, EGF also has
effects in supporting both cell cycle progression and
keratinocyte survival. EGF may help keratinocytes to survive
and proliferate in different conditions, such as middle ear
mucosa or even bony substrate. Kojima et al used in situ
hybridization to show that EGF is produced by the basal cells
of the epithelial layer of cholesteatoma [11]. The mechanism
of epithelial basal cell proliferation is through an autocrine
system via EGF and EGF-R.
Whether the cholesteatoma epithelium has more
hyperproliferative ability than normal skin is controversial,
although a previous study drew this conclusion [17]. Sudhoff
et al reported EGF immunoreactivity in neither cholestea-
toma epithelium nor in middle ear mucosa residues [18].
Zymographic analysis of culture supernatants from 10
cholesteatoma and four meatus skin samples showed no
statistically significant differences between controls and
cholesteatoma samples [19].
Previous studies used immunochemistry to investigate
proliferating cell nuclear antigen in cholesteatoma and
evaluated its proliferative activity. Their results indicate
that cholesteatoma has a similar proliferative activity to
normal postauricular skin, and that cholesteatoma itself is
not a tumor despite its clinical behavior, which is similar to
neoplastic cells [14,19,20]. Furthermore, Albino et al found
neither obvious molecular nor cellular differences among
the various types of cholesteatoma, and that cholesteatoma
epithelium behaved more like a wound-healing process
than a neoplasia [21]. Kojima et al found EGF in only 20% of
normal epidermal epithelium and 50% of cholesteatoma
epithelium [11], which suggests that other growth factor(s)
may also be needed to regulate growth of cholesteatoma
epithelium.
Although more EGF positive staining was observed in
the epithelium of active cholesteatoma, we did not observe
any significant difference between cholesteatoma and
postauricular skin in this respect. Results from the current
study suggest that EGF might influence the development of
cholesteatoma (including active and inactive types), but it
may not be the only factor. Other factors such as the envi-
ronment of the cholesteatoma, other growth factors, and
inflammatory status may also play a role [4]. This observation
seems to support the hypothesis that cholesteatoma
epithelium has similar proliferative activity to postauricular
skin tissue or benign tumor [22]. Bujia et al reported that
there were close similarities between psoriasis and middle
ear cholesteatoma concerning hyperproliferative behavior
[3]. EGF from squamous epithelium, endothelium, and
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fibroblasts may play an important role as one of the
biochemical factors by binding to EGF receptors through an
autocrine or paracrine mechanism. It is hoped that further
studies will provide better understanding of this interaction.
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